Homology medicines, inc. (FIXX)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Assets
Current assets:
Cash and cash equivalents

143,372

53,774

77,559

115,566

40,839

38,220

36,038

94,960

46,213

51,575

Short-term investments

91,557

208,614

192,113

180,230

147,128

176,517

201,505

160,547

70,519

78,084

Prepaid expenses and other current assets

3,404

4,189

4,407

2,973

2,535

6,948

8,322

6,074

3,672

1,945

Total current assets

238,333

266,577

274,079

298,769

190,502

221,685

245,866

261,582

120,404

131,604

Property and equipment, net

42,566

42,716

41,406

41,113

40,984

35,637

20,740

6,942

3,828

3,154

Right-of-use assets

6,615

-

-

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

266

-

-

-

3,072

1,000

Restricted cash

1,274

1,274

1,274

1,274

1,274

1,772

1,789

1,789

1,772

1,772

Total assets

288,788

310,567

316,759

341,156

233,026

259,094

268,396

270,314

129,078

137,530

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

7,398

2,608

8,798

8,334

11,794

15,732

11,120

5,017

3,776

2,538

Accrued expenses and other liabilities

6,949

7,644

7,818

5,306

3,792

5,040

3,847

2,358

2,258

2,860

Operating lease liabilities

2,331

-

-

-

-

-

-

-

-

-

Deferred rent

-

1,313

1,292

1,161

1,156

977

-

-

-

123

Deferred revenue

774

809

774

690

905

770

3,605

3,499

3,407

3,341

Total current liabilities

17,452

12,374

18,682

15,491

17,647

22,519

18,573

10,875

9,442

8,862

Non-current liabilities:
Operating lease liabilities, net of current portion

14,821

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

9,544

9,888

10,326

10,592

9,470

7,318

2,893

1,552

291

Deferred revenue, net of current portion

29,974

30,142

30,367

30,597

30,523

30,750

29,743

29,747

29,846

30,069

Total liabilities

62,247

52,060

58,937

56,414

58,762

62,739

55,636

43,516

40,840

39,222

Commitments and contingencies (Note 7)

-

-

-

-

-

-

0

0

0

-

Total convertible preferred stock

-

-

-

-

-

-

-

-

137,762

137,762

Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding

-

-

-

-

-

-

0

0

-

-

Common stock, $0.0001 par value; 200,000,000 shares authorized; 45,212,190 and 45,138,408 shares issued as of March 31, 2020 and December 31, 2019, respectively; and 45,206,066 and 45,116,742 shares outstanding as of March 31, 2020 and December 31, 2019, respectively

4

4

4

4

3

3

3

3

0

-

Additional paid-in capital

461,561

457,994

433,071

430,432

293,865

292,187

291,171

290,442

1,264

800

Accumulated other comprehensive gain (loss)

-19

183

254

186

6

-77

-20

-48

-86

-73

Accumulated deficit

-235,005

-199,674

-175,507

-145,880

-119,610

-95,758

-78,394

-63,598

-50,703

-40,181

Total stockholders’ equity

226,541

258,507

257,822

284,742

174,264

196,355

212,760

226,798

-49,524

-39,454

Total liabilities and stockholders' equity

288,788

310,567

316,759

341,156

233,026

259,094

268,396

270,314

129,078

137,530

Series A Convertible Preferred Stock
Total convertible preferred stock

-

-

-

-

-

-

-

-

-

42,994

Series B Convertible Preferred Stock
Total convertible preferred stock

-

-

-

-

-

-

-

-

-

94,768